Pre-Open Movers 10/10: (KALV) (ANAB) (VICL) Higher; (JBL) (LLY) (AXTA) Lower (more...)

October 10, 2017 9:28 AM EDT
Get Alerts KALV Hot Sheet
Price: $19.18 -1.74%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Today's Pre-Open Stock Movers

KalVista Pharmaceuticals (NASDAQ: KALV) 112% HIGHER; entered into a collaboration agreement with Merck (NYSE: MRK) for KVD001, the Company’s investigational intravitreal (IVT) injection candidate currently in development for potential treatment of diabetic macular edema (DME), as well as future oral DME compounds based upon plasma kallikrein inhibition.

AnaptysBio, Inc. (NASDAQ: ANAB) 44.4% HIGHER;, in an ongoing Phase 2a clinical trial in adult patients with moderate-to-severe atopic dermatitis. After a single dose of ADSB020, 75 percent of patients achieved an Eczema Area Severity Index (EASI) score improvement of 50 percent relative to enrollment baseline (EASI-50) at day 15, 83 percent of patients achieved EASI-50 at day 29 and 75 percent of patients achieved EASI-50 at day 57. All 12 patients achieved EASI-50 at one or more timepoints through Day 57 post-ANB020 administration. ANB020 was generally well tolerated in all patients as of this interim analysis.

Helios and Matheson Analytics (NASDAQ: HMNY) 14.4% HIGHER; continued momentum

Vical Incorporated (NASDAQ: VICL) 12% HIGHER; announced today that the last patient completed their final assessment during the one year follow-up period in the multinational Phase 3 registration trial of ASP0113 in hematopoietic cell transplant (HCT) recipients. The trial completed enrollment in September 2016 with a total of 515 subjects. The primary endpoint of the trial is a composite of overall mortality and cytomegalovirus (CMV) end-organ disease which will be assessed one year after transplantation. Astellas Pharma Inc. (“Astellas”) expects top-line data to be available in the first quarter of 2018.

MannKind (NASDAQ: MNKD) 11.3% HIGHER; H.C. Wainwright initiates coverage with a Buy rating and a price target of $7.00.

MiMedx Group, Inc. (NASDAQ: MDXG) 5.8% HIGHER; Q3 2017 revenue of $84.6 million exceeded MiMedx guidance range of $79 to $80 million

Ichor Holdings, Ltd. (NASDAQ: ICHR) 4.8% HIGHER; announced that the company has entered into a substantial agreement to produce liquid delivery systems for one of its key customers.

Jabil Circuit (NYSE: JBL) 4% LOWER; Goldman Sachs downgraded from Neutral to Sell with a price target of $26.00 (from $28.00).

Abeona Therapeutics (NASDAQ: ABEO) 3.8% HIGHER; Citi initiates coverage with a Buy rating and a price target of $32.00.

NVIDIA (NASDAQ: NVDA) 3.7% HIGHER; company unveiled its next-gen chips for fully autonomous cars

Palo Alto Networks (NYSE: PANW) 2.5% HIGHER; Morgan Stanley upgraded from Equalweight to Overweight with a price target of $185.00 (from $150.00).

Eli Lilly and Company (NYSE: LLY) 2.4% LOWER; announced that its Phase 3 JUNIPER study evaluating Verzenio (abemaciclib), a cyclin-dependent kinase (CDK)4 and CDK6 inhibitor, as monotherapy in KRAS-mutated, advanced non-small lung cancer (NSCLC) did not meet its primary endpoint of overall survival (OS). However, an analysis of the secondary study endpoints of both progression-free survival (PFS) and overall response rate (ORR) showed evidence of monotherapy activity in the abemaciclib arm. In addition, the control arm showed a higher overall survival rate than expected based on historical data in this setting. Lilly will submit the data for presentation at a medical meeting in 2018.

Axalta Coating Systems (NYSE: AXTA) 2.3% LOWER; Citi downgraded from Neutral to Sell with a price target of $25.00 (from $31.00).

Express Scripts Holding Company (NASDAQ: ESRX) 1% LOWER; reached an agreement to acquireprivately-held eviCore healthcare, the industry leader in evidence-based medical benefit management services, for $3.6 billion. Combining Express Scripts' leading pharmacy benefit management offering and eviCore's highly complementary medical benefits management (MBM) platform will create a uniquely comprehensive patient benefit management solution.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Goldman Sachs, Citi, Morgan Stanley, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, H.C. Wainwright